These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

88 related articles for article (PubMed ID: 19051381)

  • 1. Words of wisdom. Re: efficacy of sunitinib and sorafenib in metastatic papillary and chromophobe renal cell carcinoma.
    Bedke J; Pelzer AE
    Eur Urol; 2008 Nov; 54(5):1200-1. PubMed ID: 19051381
    [No Abstract]   [Full Text] [Related]  

  • 2. Efficacy of sunitinib and sorafenib in metastatic papillary and chromophobe renal cell carcinoma.
    Choueiri TK; Plantade A; Elson P; Negrier S; Ravaud A; Oudard S; Zhou M; Rini BI; Bukowski RM; Escudier B
    J Clin Oncol; 2008 Jan; 26(1):127-31. PubMed ID: 18165647
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Re: efficacy of sunitinib and sorafenib in metastatic papillary and chromophobe renal cell carcinoma.
    Shuch B; Belldegrun A
    Eur Urol; 2008 May; 53(5):1085-6. PubMed ID: 18485320
    [No Abstract]   [Full Text] [Related]  

  • 4. Outcome of Patients With Metastatic Chromophobe Renal Cell Carcinoma Treated With Sunitinib.
    Keizman D; Sarid D; Lee JL; Sella A; Gottfried M; Hammers H; Eisenberger MA; Carducci MA; Sinibaldi V; Neiman V; Rosenbaum E; Peer A; Neumann A; Mermershtain W; Rouvinov K; Berger R; Yildiz I
    Oncologist; 2016 Oct; 21(10):1212-1217. PubMed ID: 27382030
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Comparison of efficacy between sorafenib and sunitinib as first-line therapy for metastatic renal cell carcinoma and analyze prognostic factors for survival].
    Cai W; Yuan YC; Li MY; Kong W; Dong BJ; Chen YH; Zhang J; Xue W; Huang YR; Zhou LX; Huang JW
    Zhonghua Zhong Liu Za Zhi; 2018 May; 40(5):384-389. PubMed ID: 29860767
    [No Abstract]   [Full Text] [Related]  

  • 6. Efficacy and safety of sorafenib versus sunitinib as first-line treatment in patients with metastatic renal cell carcinoma: largest single-center retrospective analysis.
    Sheng X; Chi Z; Cui C; Si L; Li S; Tang B; Mao L; Lian B; Wang X; Yan X; Guo J
    Oncotarget; 2016 May; 7(19):27044-54. PubMed ID: 26894858
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy of sequential therapies with sorafenib-sunitinib versus sunitinib-sorafenib in metastatic renal cell carcinoma: A systematic review and meta-analysis.
    Wen T; Xiao H; Luo C; Huang L; Xiong M
    Oncotarget; 2017 Mar; 8(12):20441-20451. PubMed ID: 28099901
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of efficacy, safety, and quality of life between sorafenib and sunitinib as first-line therapy for Chinese patients with metastatic renal cell carcinoma.
    Cai W; Kong W; Dong B; Zhang J; Chen Y; Xue W; Huang Y; Zhou L; Huang J
    Chin J Cancer; 2017 Aug; 36(1):64. PubMed ID: 28789709
    [TBL] [Abstract][Full Text] [Related]  

  • 9. SWITCH: A Randomised, Sequential, Open-label Study to Evaluate the Efficacy and Safety of Sorafenib-sunitinib Versus Sunitinib-sorafenib in the Treatment of Metastatic Renal Cell Cancer.
    Eichelberg C; Vervenne WL; De Santis M; Fischer von Weikersthal L; Goebell PJ; Lerchenmüller C; Zimmermann U; Bos MM; Freier W; Schirrmacher-Memmel S; Staehler M; Pahernik S; Los M; Schenck M; Flörcken A; van Arkel C; Hauswald K; Indorf M; Gottstein D; Michel MS
    Eur Urol; 2015 Nov; 68(5):837-47. PubMed ID: 25952317
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects and Side Effects of Using Sorafenib and Sunitinib in the Treatment of Metastatic Renal Cell Carcinoma.
    Randrup Hansen C; Grimm D; Bauer J; Wehland M; Magnusson NE
    Int J Mol Sci; 2017 Feb; 18(2):. PubMed ID: 28230776
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Everolimus Versus Sunitinib Prospective Evaluation in Metastatic Non-Clear Cell Renal Cell Carcinoma (ESPN): A Randomized Multicenter Phase 2 Trial.
    Tannir NM; Jonasch E; Albiges L; Altinmakas E; Ng CS; Matin SF; Wang X; Qiao W; Dubauskas Lim Z; Tamboli P; Rao P; Sircar K; Karam JA; McDermott DF; Wood CG; Choueiri TK
    Eur Urol; 2016 May; 69(5):866-74. PubMed ID: 26626617
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparative efficacy of sunitinib versus sorafenib as first-line treatment for patients with metastatic renal cell carcinoma.
    Park SJ; Lee JL; Park I; Park K; Ahn Y; Ahn JH; Lee DH; Ahn S; Song C; Hong JH; Kim CS; Ahn H
    Chemotherapy; 2012; 58(6):468-74. PubMed ID: 23548259
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A critical appraisal of systemic treatment options for metastatic non-clear cell renal cell carcinoma.
    Ismail S; Meskawi M; Hansen J; Bianchi M; Tian Z; Latour M; Graefen M; Montorsi F; Trinh QD; Perrotte P; Karakiewicz PI; Sun M
    Crit Rev Oncol Hematol; 2014 Apr; 90(1):49-57. PubMed ID: 24411587
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Role of sunitinib and sorafenib in the treatment of metastatic renal cell carcinoma.
    Hiles JJ; Kolesar JM
    Am J Health Syst Pharm; 2008 Jan; 65(2):123-31. PubMed ID: 18192256
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sequential use of the tyrosine kinase inhibitors sorafenib and sunitinib in metastatic renal cell carcinoma: a retrospective outcome analysis.
    Eichelberg C; Heuer R; Chun FK; Hinrichs K; Zacharias M; Huland H; Heinzer H
    Eur Urol; 2008 Dec; 54(6):1373-8. PubMed ID: 18692304
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antitumor effects of sunitinib or sorafenib in patients with metastatic renal cell carcinoma who received prior antiangiogenic therapy.
    Tamaskar I; Garcia JA; Elson P; Wood L; Mekhail T; Dreicer R; Rini BI; Bukowski RM
    J Urol; 2008 Jan; 179(1):81-6; discussion 86. PubMed ID: 17997441
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sequential sorafenib and sunitinib for renal cell carcinoma.
    Sablin MP; Negrier S; Ravaud A; Oudard S; Balleyguier C; Gautier J; Celier C; Medioni J; Escudier B
    J Urol; 2009 Jul; 182(1):29-34; discussion 34. PubMed ID: 19447417
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Parvalbumin is constantly expressed in chromophobe renal carcinoma.
    Martignoni G; Pea M; Chilosi M; Brunelli M; Scarpa A; Colato C; Tardanico R; Zamboni G; Bonetti F
    Mod Pathol; 2001 Aug; 14(8):760-7. PubMed ID: 11504835
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Words of wisdom: Re: Pazopanib versus sunitinib in metastatic renal-cell carcinoma.
    Sun M; Trinh QD; Perrotte P; Karakiewicz PI
    Eur Urol; 2014 May; 65(5):1014-5. PubMed ID: 24646500
    [No Abstract]   [Full Text] [Related]  

  • 20. Words of wisdom: Re: Pazopanib versus sunitinib in metastatic renal-cell carcinoma.
    Ouzaid I; Rini B
    Eur Urol; 2014 Mar; 65(3):667-8. PubMed ID: 24484761
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.